search
Back to results

Precision Diagnosis for Intraoperative Frozen Section of Early Stage Lung Cancer

Primary Purpose

Lung Cancer

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
microscope
immunostaining
NGS
Sponsored by
Shanghai Chest Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Lung Cancer focused on measuring Early stage lung adenocarcinoma, Intraoperative frozen section, Diagnostic criteria

Eligibility Criteria

40 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients with suspected pulmonary nodules (5~20 mm) by chest CT scan;
  2. Patients received surgical operation.

Exclusion Criteria:

  1. Patients compliance is poor and cannot accept follow-up;
  2. Patients nursing or pregnant;
  3. Patients with a history of any cancer;
  4. Patients with confirmed pathological diagnosis or received radiotherapy or chemotherapy or target therapy preoperatively.

Sites / Locations

  • Shanghai Chest HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

OCT treatment

OCT free

Arm Description

Randomly assigned patients whose small pulmonary nodules are inflated with the diluted OCT medium (2:3) used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS (next-generation sequencing) for driver mutations.

Randomly assigned patients whose small pulmonary nodules are uninflated with OCT used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS for driver mutations.

Outcomes

Primary Outcome Measures

Comparison of histopathological characteristics between intraoperative frozen section and paraffin section for patients with early stage lung adenocarcinoma

Secondary Outcome Measures

Detection of CD31/CD34, D2-40, Ki67 and p53 among different subtypes of early stage lung adenocarcinoma by immunohistochemical (IHC) analysis
Comparison of mutation profiles among different subtypes of early stage lung adenocarcinoma by tissue microdissection and subsequent next generation sequencing (NGS)
Verification of the driver mutations from NGS results using droplet digital PCR (ddPCR) in early stage lung adenocarcinoma.

Full Information

First Posted
October 19, 2016
Last Updated
October 25, 2016
Sponsor
Shanghai Chest Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02941003
Brief Title
Precision Diagnosis for Intraoperative Frozen Section of Early Stage Lung Cancer
Official Title
Establishment and Evaluation for Pathological Diagnostic Criteria of Intraoperative Frozen Section of Early Stage Lung Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Unknown status
Study Start Date
February 2016 (undefined)
Primary Completion Date
December 2018 (Anticipated)
Study Completion Date
October 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shanghai Chest Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is: To establish a set of diagnostic criteria of intraoperative frozen section of early stage lung adenocarcinoma, including clinicopathologic and molecular characteristics. To assess its clinical usefulness in guiding surgical procedure for early stage lung adenocarcinoma.
Detailed Description
The detection rate of small pulmonary nodules is increasing due to the widespread use of high-resolution computed tomography (CT) screening in clinical practice. These minute pulmonary nodules are suggestive of atypical adenomatous hyperplasia (AHH), adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and invasive adenocarcinoma. Hence, the precision diagnosis of intraoperative frozen section is particularly imperative for its fundamental role in assess indeterminate lung lesions and guide the extent of subsequent surgical procedure. However, it is still difficult for the surgical pathologist to apply the various features according to the newly revised WHO classification of lung adenocarcinoma (2015) to guide surgical management due to their unascertained accuracy or heterogeneity of lung cancer or technique problem. Therefore, the establishment and assessment for a set of diagnostic criteria of intraoperative frozen section of early stage lung adenocarcinoma are our primary aim in this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer
Keywords
Early stage lung adenocarcinoma, Intraoperative frozen section, Diagnostic criteria

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
Participant
Allocation
Randomized
Enrollment
540 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
OCT treatment
Arm Type
Experimental
Arm Description
Randomly assigned patients whose small pulmonary nodules are inflated with the diluted OCT medium (2:3) used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS (next-generation sequencing) for driver mutations.
Arm Title
OCT free
Arm Type
Experimental
Arm Description
Randomly assigned patients whose small pulmonary nodules are uninflated with OCT used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS for driver mutations.
Intervention Type
Device
Intervention Name(s)
microscope
Intervention Description
Detection of of histopathological characteristics of OCT treatment or OCT free samples from patients .
Intervention Type
Other
Intervention Name(s)
immunostaining
Intervention Description
Detection of CD31/CD34, D2-40, Ki67 and p53 immunostaining of OCT treatment or OCT free samples from patients .
Intervention Type
Device
Intervention Name(s)
NGS
Other Intervention Name(s)
Illumina Nexseq500
Intervention Description
The investigators used the device to detect the gene mutations of OCT treatment or OCT free samples obtained from part of the patients.
Primary Outcome Measure Information:
Title
Comparison of histopathological characteristics between intraoperative frozen section and paraffin section for patients with early stage lung adenocarcinoma
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Detection of CD31/CD34, D2-40, Ki67 and p53 among different subtypes of early stage lung adenocarcinoma by immunohistochemical (IHC) analysis
Time Frame
6 months
Title
Comparison of mutation profiles among different subtypes of early stage lung adenocarcinoma by tissue microdissection and subsequent next generation sequencing (NGS)
Time Frame
6 months
Title
Verification of the driver mutations from NGS results using droplet digital PCR (ddPCR) in early stage lung adenocarcinoma.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with suspected pulmonary nodules (5~20 mm) by chest CT scan; Patients received surgical operation. Exclusion Criteria: Patients compliance is poor and cannot accept follow-up; Patients nursing or pregnant; Patients with a history of any cancer; Patients with confirmed pathological diagnosis or received radiotherapy or chemotherapy or target therapy preoperatively.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jie Zhang, MD, MS
Phone
(+86)18017321572
Email
18017321572@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Keke Yu, MD, PhD
Phone
(+86)18930859590
Email
ykkxx@shchest.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jie Zhang, MD, MS.
Organizational Affiliation
Shanghai Chest Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shanghai Chest Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200030
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jie Zhang, MD, MS
Phone
(+86)18017321572
Email
18017321572@163.com
First Name & Middle Initial & Last Name & Degree
Keke Yu, MD, PhD
Phone
(+86)18930859590
Email
ykkxx@shchest.org

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Precision Diagnosis for Intraoperative Frozen Section of Early Stage Lung Cancer

We'll reach out to this number within 24 hrs